Several HER2-targeted therapies have shown efficacy in clinical trials and are approved for the treatment of breast cancer and gastric cancer, including monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs)5–11. Here, ERBB2 is linked to breast cancer.